Lytix Biopharma (LYTIX) Q4 2025 earnings summary

Executive summary

• Entered a decisive new phase with strong clinical data, especially for ruxotemitide and LTX-401, and expanded commercialization opportunities.

• Interim NeoLIPA study in melanoma showed 44% pathological complete response and 55% major pathological response among first 9 patients, shaping future development and regulatory strategy.

• Partnership with Verrica Pharmaceuticals advanced, with promising immune-response data in basal cell carcinoma and preparations for pivotal Phase III trial.

• NOK 77.3 million raised in January 2026 via private placement and subsequent offering, strengthening the balance sheet for key milestones.

• Leadership and board enhanced to support late-stage execution and commercial readiness.

Financial highlights

• Q4 2025 operating expenses were NOK 21.2 million, down from NOK 33 million year-over-year, mainly due to reduced R&D activity.

• Cash and short-term investments at Q4 2025 end were NOK 72 million, with NOK 77.3 million raised post-quarter.

• Total liabilities at Q4 2025 were NOK 20 million, down from NOK 39 million year-over-year.

• Loss for Q4 2025 was NOK 18.7 million, improved from NOK 31.9 million in Q4 2024.

• Cash flow from operations was negative NOK 29.5 million in H2 2025, an improvement from negative NOK 33.1 million in H2 2024.

Outlook and guidance

• Well-capitalized into mid-2027, supporting clinical and partnering milestones, with focus on pivotal studies and commercialization.

• NeoLIPA topline results expected in H2 2026; pivotal study for ruxotemitide in preparation.

• LTX-401 clinical entry targeted for 2027, with ongoing evaluation of strategic development opportunities.

• Actively pursuing capital raising and pharma partnerships to fund pivotal studies.

• Expectation of continued disciplined execution, targeted investment, and strategic collaboration.